Skip to main content
AACR Project GENIE v19.0 · 21,017 myeloid samples Panel-adjusted Fisher's exact with Benjamini-Hochberg FDR N=1 case study · Not clinical guidance

DDX41+SETBP1 Deep Dive

Germline/somatic DDX41 co-occurrence with SETBP1 in myeloid neoplasms

DDX41+SETBP1 co-occurrence analysis across GENIE v19.0 patients with myeloid or histiocytic cancer types. DDX41 germline mutations define a distinct myeloid neoplasm subtype. This page examines their overlap with SETBP1 somatic mutations in the context of a five-driver mutation profile.
DDX41+SETBP1
2 patients
O/E=4.26, p=0.079
DDX41 Coverage
16 panels
3,224 patients covered (myeloid + histiocytic cohort)
BH q-value
0.649
Not significant after correction
Novel Variants
1
EZH2 V662A (0 PubMed hits); PTPN11 E76Q is recurrent (11 GENIE samples)

Five-Driver Context

Classifying EZH2 V662A as Likely Pathogenic (PP3_Strong on 6/7 concordant computational predictors; EVE dissents at 0.7825, Uncertain at its class25 calibration) is a research classification; ClinVar lists the variant as a VUS. The index patient carries four confirmed driver mutations plus EZH2 V662A. The exact five-variant combination has no estimable population frequency. Zero in 8,655 patients bounds it below 1 in 2,889 (95%, exact binomial).

ClinGen Gene-Disease Validity

GeneDiseaseValidityClassification Date
DNMT3ATatton-Brown-Rahman overgrowth syndrome (germline)Definitive2023-06-08
IDH2Mitochondrial disease (germline)Definitive2023-01-30
SETBP1Schinzel-Giedion syndrome (germline)Definitive2021-02-16
PTPN11Noonan syndrome (germline)Definitive2018-07-24
EZH2Weaver syndrome (germline)Definitive2022-08-03
DDX41DDX41-related hematologic malignancy predisposition syndromeDefinitive2020-07-30
ClinGen's gene-disease validity file (downloaded 2 November 2026) has a Definitive curation for all 6 genes, but only the DDX41 curation concerns a myeloid condition (inherited predisposition). The other five are germline developmental or metabolic syndromes. ClinGen has no gene-disease validity curation of these genes for somatic AML or MDS, so this table does not by itself establish myeloid driver status.

DDX41+SETBP1 Co-occurrence

DDX41 germline mutations 7
[7] C 2015
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell (2015)
6
[6] H 2023
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood (2023)
are an active area of myeloid neoplasm research. DDX41-mutant MN defy current prognostic schemes 8
[8] C 2026
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study. Leukemia (2026)
. This analysis found 2 co-mutated patients with SETBP1 mutations 2
[2] H 2013
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013)
1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
in GENIE v19.0 17
[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
among 3,224 patients (one sample each, GENIE myeloid and histiocytic cancer types) whose panel covered both genes (16 panels). The co-occurrence has O/E=4.26, Fisher's exact p=0.079, BH-adjusted q=0.649. All patients are from UHN (Toronto), both AML, and both share EZH2 as an additional co-mutated gene.
Sample IDCancer TypeDDX41 MutationSETBP1 MutationOther GenesTotal Mutations
withheld (GENIE terms)AMLp.G402W + p.M1?p.G870S (SKI)ASXL1/CBL/DNMT3A/EZH2/RUNX18
withheld (GENIE terms)AMLp.Q329Rfs*7p.N454D (non-SKI)EZH23
Note: Both patients from University Health Network (Toronto). Both AML. Both share EZH2 co-mutation.

PTPN11 E76Q Knowledge Gap

Semantic Scholar searches (6 queries: 4 patient variants, 1 co-occurrence and 1 quadruple-mutation query; EZH2 V662A was not queried) returned 144 unique publications. Type 1 progression mutations (PTPN11, IDH2) 15
[15] H 2017
Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet (2017)
are key to clonal evolution. Yet PTPN11 E76Q returned only 2 publications, the fewest of any variant queried. By comparison, DNMT3A R882H returned 100 (the search cap) and IDH2 R140Q returned 19. This variant is significantly understudied relative to its clinical significance: E76Q is a recurrent activating mutation in the SHP2 phosphatase domain, found in both de novo and therapy-related myeloid neoplasms.

Patient 2642: Closest Match

Patient 2642 is from the Beat AML study (OHSU, Cancer Cell 2022; 903 patients, searched via cBioPortal), not from GENIE. This patient carries IDH2 R140Q + SETBP1 G870S + PTPN11 N308S: the same IDH2 and SETBP1 variants as the index patient, but a different PTPN11 variant (N308S, not E76Q) and no DNMT3A mutation. It is the only patient with IDH2, PTPN11 and SETBP1 mutations together in the databases searched; GENIE v19.0 17
[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
has 0 samples with this combination, even at gene level. No patient in any database has all four mutations. With EZH2 V662A classified Likely Pathogenic (research classification), the gap widens further: no EZH2 mutation is listed in either of Patient 2642's whole-exome samples, making this closest match even less close to the full quintuple profile. Clonal succession 15
[15] H 2017
Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet (2017)
modeling and IPSS-M 13
[13] E 2022
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid (2022)
scoring would both be needed to fully characterize this case.
Property Value
Patient ID2642 (Beat AML)
Matching mutationsIDH2 R140Q, SETBP1 G870S (exact); PTPN11 N308S (same gene, not E76Q)
Missing from quadrupleDNMT3A R882H, PTPN11 E76Q
DatabaseBeat AML (OHSU, Cancer Cell 2022) via cBioPortal; not in GENIE v19.0
Denominator903 Beat AML patients
Frequency1 / 903 (0.11%), IDH2+PTPN11+SETBP1 at gene level

Note on DDX41 Numbers

An earlier, superseded analysis (21 March 2026; 14,601 patients selected by the words "leukemia" or "myeloid" in the cancer type, which also took in lymphoid leukemias; 271 SETBP1 patients) found 3 co-mutated patients with O/E=5.16, p=0.020. The current analysis (3 November 2026; myeloid OncoTree codes only, one sample per patient, 222 SETBP1 patients, 72 on DDX41-covered panels) finds 2 patients with O/E=4.26, p=0.079, not significant (BH q=0.153 among the SETBP1 partner genes, 0.649 among all DDX41 pairs). Both runs used the same >20 coding mutation cutoff. The difference comes from the cohort definition and panel handling, not the hypermutation filter.
Analysis SETBP1 Patients DDX41+SETBP1 O/E p-value BH q-value
32-gene filter 271 3 5.16 0.020 <0.05 (no exact value kept)
Current (myeloid OncoTree, per patient) 72 2 4.26 0.079 NS
References
  1. Polprasert C, Schulze I, Sekeres MA, Makishima H, et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell (2015). PubMed
  2. Makishima H, Saiki R, Nannya Y, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood (2023). PubMed
  3. Gurnari C, Makishima H, Durmaz A, et al. DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system. Leukemia (2026). PubMed
  4. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013). PubMed
  5. Piazza R, Magistroni V, Redaelli S, et al. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018). PubMed
  6. Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013). PubMed
  7. AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017). DOI
  8. Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet (2017). PubMed
  9. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid (2022). DOI